Primary sclerosing cholangitis (PSC) is a cholestatic liver disease of unknown cause with striking geographic variation in prevalence, including marked peaks in Northern Europe and parts of the U.S. Upper Midwest. The factors that explain a greater than 30-fold worldwide variation in PSC prevalence are not fully accounted for by known risk markers. This analysis tested whether exposure to Ixodes tick-borne pathogens could be an ecological correlate and candidate trigger for primary sclerosing cholangitis.
The study compared PSC incidence across North America, Europe, and Oceania with measures of Ixodes exposure, including reported Lyme incidence, vector density proxies, and incidence of specific tick-borne infections. The author included known genetic and disease comparators such as HLA-DRB1*03 frequency and two other autoimmune liver diseases—autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC)—as controls.
A focused U.S. analysis used MarketScan claims data covering 2018–2022 (110.7 million person-years). Age- and sex-standardized PSC rates by state were correlated with 24 exposures, including county/state-level reports of tick-borne infections. Analyses used ancestry-adjusted partial correlations and additional adjustments such as latitude in regional subanalyses.
Cross-national comparisons evaluated whether PSC incidence paralleled Lyme incidence and whether patterns could be explained by HLA-DRB1*03 frequency or by the distribution of AIH and PBC. The non-Ixodes infections (for example, Ehrlichia chaffeensis, spotted fever group rickettsioses, and tularemia) and ecological variables related to rural/agricultural land use, pollution, and health-care access were examined as alternative explanatory factors.
Across countries in the examined regions, PSC incidence tracked Lyme disease incidence, with Spearman correlation coefficients reported between 0.71 and 0.87. By contrast, HLA-DRB1*03 frequency and the geographic distributions of AIH and PBC did not show the same alignment with Lyme incidence.
These cross-country correlations suggest a geographic concordance between regions of higher reported Ixodes-borne pathogen activity and higher PSC incidence.
In the U.S. MarketScan data, PSC showed geographic clustering and positive associations with incidence of specific Ixodes-borne infections. On the log scale and adjusted for ancestry, partial correlation coefficients were reported as:
In a regional block spanning the Northeast and Midwest, with further adjustment for latitude, the ancestry- and latitude-adjusted partial correlations increased to:
By contrast, non-Ixodes infections such as Ehrlichia chaffeensis, spotted fever group diseases, and tularemia showed null-to-negative correlations with PSC. Similarly, analyses did not find positive associations between PSC and rural or agricultural measures, pollution indices, or healthcare-access variables.
The author notes that certain high-latitude populations—specifically Alaska Native and Greenlandic groups—report no PSC despite having high prevalence of autoimmune liver disease and inflammatory bowel disease. These populations lack evidence of established human exposure to Ixodes-borne pathogens, which the author highlights as a contrasting observation consistent with the hypothesis under study.
The analyses are ecological and cross-sectional in nature. The author explicitly states that these data cannot establish causation; they can only identify patterns that are hypothesis-generating. Limitations intrinsic to ecological studies apply, including potential ecological fallacy, unmeasured confounding, and reliance on surveillance and claims data with variable completeness. The source does not report individual-level serologic, case–control, or mechanistic data that would be needed to support causal inference.
The observed geographic concordance between PSC incidence and measures of Ixodes-borne pathogen exposure is presented as consistent with the hypothesis that such exposures may act as triggers for PSC. The paper frames these findings as providing falsifiable predictions to guide follow-up research, specifically recommending case–control studies, targeted serologic testing in PSC patients, and animal-model experiments to evaluate causality and potential mechanisms.
The MarketScan portion of the work used de-identified secondary data and was determined exempt by the Yale University IRB. The author declares no competing interests. Analysis code and derived de-identified state-level data will be deposited in a public repository (GitHub) and archived at Zenodo with a citable DOI upon acceptance by a peer-reviewed journal; data will be made available on request during peer review.
These ecological results identify a geographically coherent pattern linking higher regional incidence of Ixodes-borne infections (including Lyme, anaplasmosis, babesiosis, and Powassan virus disease) with higher reported PSC incidence. The study does not change clinical practice but prioritizes targeted epidemiologic and mechanistic studies—case–control analyses with individual exposure and serology, and preclinical models—to test whether specific tick-borne pathogens can trigger or contribute to PSC pathogenesis.